Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix.

Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA.

J Nucl Med. 2008 Jul;49(7):1177-82. doi: 10.2967/jnumed.108.051326. Epub 2008 Jun 13.

2.

Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.

Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8.

PMID:
12654432
3.

Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ.

J Nucl Med. 2008 Feb;49(2):201-5. doi: 10.2967/jnumed.107.048520. Epub 2008 Jan 16.

4.

Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.

Valtorta S, Belloli S, Sanvito F, Masiello V, Di Grigoli G, Monterisi C, Fazio F, Picchio M, Moresco RM.

J Nucl Med. 2013 Jul;54(7):1106-12. doi: 10.2967/jnumed.112.111120. Epub 2013 May 22.

5.

Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).

Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW.

J Nucl Med. 2006 Jun;47(6):989-98.

6.

Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix.

Grigsby PW, Malyapa RS, Higashikubo R, Schwarz JK, Welch MJ, Huettner PC, Dehdashti F.

Mol Imaging Biol. 2007 Sep-Oct;9(5):278-83.

PMID:
17431727
7.

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.

O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL.

Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1493-502.

PMID:
15817355
8.

Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.

Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, Inoue T, Kawahara N.

AJNR Am J Neuroradiol. 2013 Jan;34(1):92-9. doi: 10.3174/ajnr.A3159. Epub 2012 Jun 14.

9.

In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.

Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA.

Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):844-50. Epub 2003 Apr 12.

PMID:
12692685
10.

Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.

Dence CS, Ponde DE, Welch MJ, Lewis JS.

Nucl Med Biol. 2008 Aug;35(6):713-20. doi: 10.1016/j.nucmedbio.2008.06.001.

11.

Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.

Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ.

J Nucl Med. 2001 Apr;42(4):655-61.

12.

Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.

Hansen AE, Kristensen AT, Law I, McEvoy FJ, Kjær A, Engelholm SA.

Radiother Oncol. 2012 Mar;102(3):424-8. doi: 10.1016/j.radonc.2011.10.021. Epub 2011 Nov 24.

PMID:
22119225
13.

A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.

Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ.

Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1171-82.

PMID:
11240261
14.

Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines.

Vāvere AL, Lewis JS.

Nucl Med Biol. 2008 Apr;35(3):273-9. doi: 10.1016/j.nucmedbio.2007.11.012.

15.

PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.

Zhang T, Das SK, Fels DR, Hansen KS, Wong TZ, Dewhirst MW, Vlahovic G.

AJR Am J Roentgenol. 2013 Nov;201(5):W698-706. doi: 10.2214/AJR.12.9698.

16.

Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.

Vāvere AL, Lewis JS.

Dalton Trans. 2007 Nov 21;(43):4893-902. Epub 2007 Sep 25.

PMID:
17992274
17.

Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.

Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, Okazawa H.

J Nucl Med. 2009 Dec;50(12):1948-53. doi: 10.2967/jnumed.109.069021. Epub 2009 Nov 12.

18.

Assessing tumor hypoxia in head and neck cancer by PET with ⁶²Cu-diacetyl-bis(N⁴-methylthiosemicarbazone).

Sato Y, Tsujikawa T, Oh M, Mori T, Kiyono Y, Fujieda S, Kimura H, Okazawa H.

Clin Nucl Med. 2014 Dec;39(12):1027-32. doi: 10.1097/RLU.0000000000000537.

PMID:
25140555
19.

Preclinical studies of [61Cu]ATSM as a PET radiopharmaceutical for fibrosarcoma imaging.

Jalilian AR, Rostampour N, Rowshanfarzad P, Shafaii K, Kamali-Dehghan M, Akhlaghi M.

Acta Pharm. 2009 Mar;59(1):45-55. doi: 10.2478/v10007-009-0008-9.

PMID:
19304557
20.

Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.

Bonnitcha PD, Bayly SR, Theobald MB, Betts HM, Lewis JS, Dilworth JR.

J Inorg Biochem. 2010 Feb;104(2):126-35. doi: 10.1016/j.jinorgbio.2009.10.009. Epub 2009 Oct 24.

Items per page

Supplemental Content

Write to the Help Desk